GLP1R and type 2 diabetes mellitus: For example, while semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with T2D and chronic kidney disease [30], it is not known which mechanism(s) or processes from GLP-1/GLP-1R action delay the course of diabetic kidney disease, making these findings hypothesis-generating [31].